Your browser is no longer supported. Please, upgrade your browser.
Settings
AMGN Amgen Inc. daily Stock Chart
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E14.10 EPS (ttm)10.01 Insider Own0.13% Shs Outstand747.00M Perf Week-2.00%
Market Cap105.47B Forward P/E11.27 EPS next Y12.53 Insider Trans-0.30% Shs Float741.71M Perf Month2.11%
Income7.59B PEG1.87 EPS next Q2.80 Inst Own79.90% Short Float1.05% Perf Quarter-16.86%
Sales22.56B P/S4.67 EPS this Y35.20% Inst Trans-1.89% Short Ratio2.02 Perf Half Y-8.81%
Book/sh41.20 P/B3.43 EPS next Y8.37% ROA10.10% Target Price182.21 Perf Year-9.06%
Cash/sh50.84 P/C2.78 EPS next 5Y7.52% ROE25.80% 52W Range132.74 - 175.66 Perf YTD-10.73%
Dividend4.00 P/FCF374.00 EPS past 5Y13.60% ROI12.50% 52W High-19.62% Beta1.16
Dividend %2.83% Quick Ratio4.10 Sales past 5Y7.60% Gross Margin81.50% 52W Low6.36% ATR3.44
Employees17900 Current Ratio4.30 Sales Q/Q1.50% Oper. Margin41.40% RSI (14)36.82 Volatility1.99% 2.06%
OptionableYes Debt/Eq1.15 EPS Q/Q9.80% Profit Margin33.60% Rel Volume1.87 Prev Close145.11
ShortableYes LT Debt/Eq0.99 EarningsOct 27 Payout37.50% Avg Volume3.85M Price141.19
Recom2.40 SMA20-2.87% SMA50-7.43% SMA200-9.51% Volume7,030,704 Change-2.70%
Nov-08-16Initiated Mizuho Buy $164
Aug-26-16Initiated Gabelli & Co Hold
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Dec-07-16 02:45PM  Trump Vow On Drug Prices Fails To Stop Rally; Apple Retakes Prior Buy Point
02:44PM  4 Stocks Set for Dividend Hikes Next Week at Barrons.com
10:52AM  Dividend-paying stocks pull US indexes up; drugmakers drop
08:49AM  Biotech Stock Roundup: Actelion Remains in M&A Spotlight, ASH Data in Focus
08:18AM  Better Buy: Amgen Inc. vs. Pfizer at Motley Fool
Dec-06-16 04:31PM  Rivals Kite Pharma, Juno Therapeutics Tank On Cancer Data; Spark Flies
Dec-05-16 03:55PM  Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell
11:43AM  Amgen Rolls Out Kidney Disease Campaign (AMGN) at Investopedia
09:36AM  Amgen/Allergan File for EU Approval of Avastin Biosimilar
08:47AM  Amgen, Allergan File for Avastin Biosimilar in EU (AGN) at Investopedia
Dec-04-16 01:13PM  Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment
08:27AM  3 Large-Cap Stocks to Buy in December at Motley Fool
05:37AM  5 Dividend Stocks to Buy in December at Motley Fool
Dec-02-16 04:16PM  Here's How Much Trump Tax Cuts Could Boost The Stock Market
04:05PM  Amgen, Regeneron 2017 LDL-Busters Could Boost This Small-Cap Biotech
04:00PM  Amgen Announces Launch Of Blood Counts And Collaboration With StoryCorps To Record And Share Stories Of Those Impacted By Multiple Myeloma PR Newswire
09:53AM  Allergan & Amgen Looking for Approvals (AGN, AMGN) at Investopedia
09:33AM  Amgen, Allergan apply for European nod for Avastin biosimilar Reuters
09:00AM  Amgen And Allergan Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab PR Newswire
Dec-01-16 05:00PM  Bluebird Rockets On Myeloma Drug; Celgene Gets Boost
04:00PM  Amgen To Present At The Citi 2016 Global Healthcare Conference PR Newswire
02:46PM  Cytokinetics Gets $27M Milestone from Amgen (AMGN, CYTK) at Investopedia
09:40AM  Bluebird Bio, Celgene Multiple Myeloma Therapy Strong In 9-Patient Study
Nov-30-16 10:08PM  The Big Shorts Michael Burry Reveals His New Stock Picks at Insider Monkey
06:31PM  The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function In Patients With Chronic Heart Failure PR Newswire
06:30PM  The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function in Patients With Chronic Heart Failure GlobeNewswire
12:24PM  Here's Why Arrowhead Pharmaceuticals Inc. Is Being Obliterated Today at Motley Fool
10:00AM  Amgen Announces Presentation Of New Data In Acute Lymphoblastic Leukemia, Multiple Myeloma And Immune Thrombocytopenia At ASH 2016 PR Newswire
09:33AM  Better Buy: Biogen Inc. vs. Amgen at Motley Fool
08:38AM  Pfizer/Merck KGaA: Priority Review for Cancer Drug Avelumab
Nov-29-16 07:11PM  Cramer's lightning round: Stocks down so low with a flashing buy signal at CNBC
07:00PM  Cramer Remix: why you shouldnt sell before year end
05:04PM  Falling Revenue in Allergans US General Medicines Segment
03:04PM  Allergans US Specialized Therapeutics Segment in 3Q16
02:00PM  AbbVies Financial Guidance for 2017
08:03AM  3 Top Dividend Stocks to Buy in 2017 at Motley Fool
07:00AM  [$$] 'Brain training' healthcare digital games target dementia at Financial Times
Nov-28-16 10:05AM  Humira Has Been a Key Growth Driver for AbbVie in 2016
07:35AM  Short Sellers Grow More Aggressive on Major Biotechs
Nov-25-16 08:04AM  Key Investor Insights into Eli Lillys Recent Developments
Nov-24-16 08:37AM  The 3 Best Dividend Growth ETFs for 2017 at Forbes
Nov-23-16 04:43PM  Is Amgen, Inc. (AMGN) A Good Stock To Buy Now? at Insider Monkey
10:29AM  5 Biotech Stocks George Soros Is Buying at Motley Fool
Nov-22-16 06:30PM  6 Worthy Dividend Stocks Down 10% or More
04:53PM  Alder Keels For Sixth Day After EU Upholds Teva Migraine Patent
03:04PM  Understanding Eli Lillys Business Segments by 3Q16 Performance
09:40AM  Jefferies Makes Another Huge Addition to Franchise Picks Stocks Portfolio at 24/7 Wall St.
08:08AM  J&J Immunotherapy Darzalex OK'd for Label Expansion by FDA
08:05AM  SD-809 Could Be a Strong Growth Driver for Teva Pharmaceutical
Nov-21-16 04:07PM  Amgen, Biogen, Celgene Eye M&A In Trump's 'Pro-Biotech' World
04:06PM  Big Stock Buyback Boost Coming From Trump Tax Proposal: Goldman Sachs
10:50AM  The Positive Performance of the Healthcare Sector
09:59AM  Novartis (NVS) Reports Favorable Data on Enbrel Biosimilar
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Cisco, NextEra Energy, AbbVie and eBay
Nov-18-16 05:27PM  Aegerion's Juxtapid Gets Pricing Authorization in Japan
04:42PM  Drugmaker losses pull stocks lower; small-cap surge goes on
01:43PM  Top Research Reports for Cisco, Amgen & NextEra Energy
08:54AM  Novartis/Amgen Migraine Drug Positive in Phase III Study
08:02AM  Regeneron/Sanofi's Praluent CV Outcomes Study to Continue
Nov-17-16 07:27PM  Money in Medicine: The 30 drug and device makers who paid Oregon doctors the most at bizjournals.com
04:18PM  Amgen On Track For 2018 Migraine-Drug Launch, Beating 'Crowded Field'
11:45AM  Amgen Migraine Drug Does Well in Late Study (AMGN) at Investopedia
10:14AM  Amgen's Migraine Drug Hits Primary Endpoint in STRIVE Study
09:05AM  Early movers: WMT, BBY, SJM, SPLS, AMZN, AAPL, GOOGL, FB & more at CNBC
04:50AM  No early win for Sanofi, Regeneron cholesterol drug in study
04:47AM  Amgen, Novartis aim for big, crowded migraine market after new drug data
Nov-16-16 05:47PM  Amgen's migraine drug succeeds in late-stage trial
05:22PM  Is Immunotherapy the Next Hot Industry for Biotech Stock Investors?
05:01PM  Amgen shares tick higher on positive migraine drug study at MarketWatch
04:40PM  Amgen experiment drug reduces migraines in study
04:30PM  Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In Second Phase 3 Study PR Newswire
04:29PM  Medicines Co., Alnylam Split On Amgen-Rivaling Cholesterol-Buster
09:02AM  Amgen Files BLA for Avastin Biosimilar (AMGN, AGN) at Investopedia
08:17AM  Amgen Files for Avastin Biosimilar; Repatha Data Positive
08:12AM  Biotech Stock Roundup: Biotech Stocks Soar on Election Results, Gilead HBV Drug Approved
Nov-15-16 04:28PM  Amgen, Biogen, Eli Lilly Poised To Rocket On 'Most Important Event'
04:00PM  Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 215 To U.S. Food And Drug Administration PR Newswire
12:28PM  Repatha® (Evolocumab) Regresses Atherosclerosis In Patients With Coronary Artery Disease PR Newswire
12:07PM  Cholesterol drug shows promise to help reverse heart disease
11:45AM  Amgen cholesterol drug reduces artery-clogging plaque in study
11:45AM  Amgens Repatha Unclogs Arteries in Good Sign for Future Sales at Bloomberg
11:08AM  George Soros: There's More In That 13F Than Emerging Markets at Barrons.com
Nov-14-16 11:45AM  Amgen's Parsabiv Kidney Drug Approved in EU (AMGN) at Investopedia
09:25AM  Amgen Presents Osteoporosis Data; Parsabiv Approved in EU
09:00AM  New 'Ten To Watch' List Highlights Top Amgen Scholars Poised To Impact The Future Of Science And Medicine PR Newswire
08:00AM  4 Trade Ideas for Amgen
Nov-13-16 07:45AM  3 Drugmakers That Probably Have Lower Tax Rates Than You Do at Motley Fool
Nov-12-16 04:30PM  Results From Phase 3 BRIDGE Study Show Romosozumab Significantly Increases Bone Mineral Density In Men With Osteoporosis PR Newswire
09:44AM  The Shot Heard Round the World: First Inning of Global Reflation
Nov-11-16 06:04PM  Inside AstraZenecas Revenue Fall in 3Q16
04:00PM  European Commission Approves Parsabiv (etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adults On Hemodialysis PR Newswire
11:45AM  Amgen, Janssen to Begin Myeloma Trial (AMGN, JNJ) at Investopedia
09:35AM  Top Biotech and Health Care Stocks Set to Run on Huge Republican Sweep at 24/7 Wall St.
Nov-10-16 04:31PM  [$$] Cancer Therapeutics Startup DNAtrix Boosts Pipeline Through Licensing Deal at The Wall Street Journal
04:00PM  Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2016 PR Newswire
12:30PM  3 Reasons Trump Victory Brings New Day for Biotech at Barrons.com
08:33AM  Amgen Announces Collaboration With Janssen To Co-Fund Studies With KYPROLIS® (Carfilzomib) And DARZALEX® (Daratumumab) In Patients With Multiple Myeloma PR Newswire
07:20AM  Short Sellers Grow More Selective on Major Biotechs
Nov-09-16 04:19PM  Drug Stocks Rally On Relief Clinton Didn't Win White House +5.76%
01:18PM  Biotech: Is Today's Trump Rally Just the Beginning? at Barrons.com
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its principal products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of high cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc; UCB; Novartis AG; Bayer HealthCare Pharmaceuticals Inc; Advaxis, Inc.; Dr. Reddy's Laboratories Ltd.; and Nuevolution AB. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
de Carbonnel FrancoisDirectorSep 09Option Exercise71.645,000358,20021,171Sep 13 06:21 PM
Such Annette LouiseVP, Finance and CAOAug 02Sale174.593,000523,7587,183Aug 03 08:14 PM
Balachandran MadhavanEVP, OperationsMay 04Sale154.1230,0004,623,62455,996May 05 08:16 PM
BALTIMORE DAVIDDirectorApr 29Sale157.213,312520,68432,350May 03 07:12 PM
BALTIMORE DAVIDDirectorMar 30Option Exercise50.445,000252,20037,350Mar 31 06:01 PM
HERRINGER FRANK CDirectorMar 14Option Exercise50.445,000252,20030,608Mar 16 06:48 PM
COFFMAN VANCE DDirectorMar 09Option Exercise50.445,000252,20043,447Mar 10 06:55 PM
Bradway Robert AChairman, CEO and PresidentMar 02Option Exercise50.4484,0004,236,960447,102Mar 04 06:07 PM
Bradway Robert AChairman, CEO and PresidentMar 02Sale146.4820,0002,929,566383,102Mar 04 06:07 PM